BDX
February 6, 2025 - AI Summary
Undervalued by 112.3% based on the discounted cash flow analysis.
Market cap | $64.55 Billion |
---|---|
Enterprise Value | $82.22 Billion |
Dividend Yield | $3.89 (1.73042704626334%) |
Earnings per Share | $5.88 |
Beta | 0.45 |
Outstanding Shares | 289,505,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 37.68 |
---|---|
PEG | 13 |
Price to Sales | 3.26 |
Price to Book Ratio | 1.99 |
Enterprise Value to Revenue | 4.07 |
Enterprise Value to EBIT | 41.84 |
Enterprise Value to Net Income | 47 |
Total Debt to Enterprise | 0.22 |
Debt to Equity | 0.34 |
No data
No data
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of hea...